Skip to content
Review Open access

Targeting the DNA Damage Response in Cancer

Sep 2026 · MedComm · Vol 7 · 0 citations · 209 references
Medicine

TL;DR

A modular biomarker framework integrating genomic, functional, immune‐context, spatial and dynamic readouts to guide patient selection, treatment adaptation, and precision therapeutic decision‐making is proposed.

Abstract

The DNA damage response (DDR) is increasingly recognized not only as a genome‐maintenance network and source of synthetic‐lethal vulnerabilities, but also as a regulator of tumor immunity. DDR defects and pharmacologic inhibition can increase neoantigen formation, generate micronuclei and cytosolic nucleic acids, activate cGAS–STING, DNA‐PK–NF‐κB, and ERV‐driven RIG‐I/MDA5–MAVS signaling, and alter antigen presentation and immune checkpoint expression. However, the same processes may also promote chronic interferon tolerance, PD‐L1 induction, lymphocyte stress, myeloid suppression, extracellular cGAMP degradation, stromal exclusion, and treatment resistance. This review frames DDR targeting around damage‐to‐immunity conversion, asking when DNA damage becomes a productive antitumor immune signal and when it does not. We summarize targetable DDR modules across cancer types, examine tumor‐intrinsic and host‐cell sensing mechanisms, and discuss antigen‐processing defects, STING regulation, and microenvironmental barriers that shape divergent outcomes. We further review PARP, ATR, WEE1, ATM, and DNA‐PK inhibitor combinations with immunotherapy and other treatment modalities, emphasizing clinical evidence, scheduling, and host‐cell toxicity. Finally, we propose a modular biomarker framework integrating genomic, functional, immune‐context, spatial and dynamic readouts to guide patient selection, treatment adaptation, and precision therapeutic decision‐making.

Read PDF

Similar papers

Review Open access Aug 2026

Targeting the DNA damage response to reshape the tumor immune microenvironment

This review summarizes the major DDR pathways, their roles in tumor evolution and immune remodeling, and the rationale and limitations of combining DDR-targeted therapies with immunotherapy and discusses biomarker refinement, resistance mechanisms, and future strategies for translating genomic stress into durable antit...

Wenge Li, Xin Yu · 0 citations
Review Open access Sep 2026

The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications

Homologous recombination deficiency (HRD) is a major genomic feature of several malignancies and provides a therapeutic rationale for DNA-damaging agents and PARP inhibitors. Beyond its role in genome instability, accumulating evidence suggests that HRD also reshapes the tumor microenvironment (TME). However, the immun...

Yi-Ting Yang, Yu-Jia Yin, Sheng-Xin Rong et al. · 0 citations
Review Open access Sep 2026

Exploiting DNA Damage Tolerance for Precision Oncology

By integrating DDT inhibition with biomarkers like homologous recombination deficiency and tumor mutational burden, this work can drive synthetic lethality, sensitize tumors to genotoxic agents, suppress treatment-induced mutagenesis, and potentially enhance responses to immunotherapy.

Audesh Bhat, G. Lahane, R. Pandita et al. · 0 citations
Review Sep 2026

Radiation-Induced Cell-Death States in Cancer: Toward Biomarker-Guided Radioimmunotherapy.

This narrative review reframes radiation-induced regulated cell death around four functional outputs: antigen preservation, productive innate sensing, effector-cell access, and suppressive remodeling, and integrates tumor genotype, metabolic state, host lymphocyte reserve, spatial heterogeneity, radiation dose and fiel...

Xiao-Dong Wang, Wei Gao, Qian-Qian Wang et al. · 0 citations
Review Open access Sep 2026

Expanding Synthetic Lethality in DNA Damage Response-Defective Cancers Through Stress Phenotype-Guided Kinase Targeting

Synthetic lethality has reshaped oncology, particularly in tumours with defects in DNA damage response (DDR) pathways, yet therapeutic strategies centred on canonical DDR targets, including poly(ADP-ribose) polymerase (PARP), ataxia telangiectasia and Rad3-related protein (ATR), checkpoint kinase 1 (CHK1) and Wee1 G2 c...

Mirco Masi, Giulia Varignani, A. Cavalli et al. · 0 citations
Review Open access Sep 2026

Replication Stress Tolerance in Adult T-Cell Leukemia

This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1-mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses.

Yusuke Okamoto, Masayuki Kobayashi, Takashi Sakamoto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.